Unrelated Donor Bone Marrow Transplant for Sickle Cell Disease

submitted by: mcgheek
Jennifer Jaroscak, M.D., of MUSC Children's Hospital discusses bone marrow transplant (BMT) as a cure for patients with sickle cell disease. She describes a new reduced-intensity conditioning (RIC) regimen being trialed at MUSC for BMTs from well-matched unrelated donors in the SCURT study. RIC is safer for unrelated donor transplant because, unlike myeloablative BMTs, it suppresses but does not destroy the patient's bone marrow. Find out more about the SCURT study and reduced-intensity...

Newly Diagnosed Symptomatic Multiple Myeloma: (mSMART) Consensus Guidelines 2013

submitted by: WentzMR

Dr. Joseph Mikhael, a Hematologist from Mayo Clinic in Arizona shares results of a consensus guideline appearing in the April 2013 issue of Mayo Clinic Proceedings, which provides a rational, safe, and effective update to the changing field of multiple myeloma treatment. Available at: http://tinyurl.com/c7s3jbv

Incidence of MGUS and Estimation of Duration Before Recognition

submitted by: WentzMR
Dr. Terry Therneau, a Professor of Biostatistics at Mayo Clinic in Rochester, MN, discusses his article appearing online first and in the November 2012 issue of Mayo Clinic Proceedings, placing the surprising outcome among the statistics discovered in the study into perspective. Available at: http://www.mayoclinicproceedings.org/article/ S0025-6196(12)00634-9/fulltext

Incidence of MGUS & Estimation of Duration Before First Clinical Recognition

submitted by: WentzMR

Dr. Robert Kyle, professor of medicine, laboratory medicine and pathology, at Mayo Clinic in Rochester, MN, discusses his article appearing online first and in the November 2012 issue of Mayo Clinic Proceedings, where he defines MGUS and explains its role in the development of multiple myeloma and other blood disorders.
Available at: http://www.mayoclinicproceedings.org/article/S0025-6196(12)00634-9/fulltext

Dr Shaji K Kumar of Mayo Clinic discusses Dec 2009 Mayo Clinic Proceedings article on updated mSMART Consensus Guidelines

submitted by: mcgheekkm
Dr. Shaji K Kumar, Associate Professor of Hematology and Medicine at Mayo Clinic in Rochester, MN, discusses updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines (direct link available at http://tiny.cc/V2dk9 or visit journal at www.mayoclinicproceedings.com ). The identification of well-defined and reproducible prognostic factors and introduction of new therapies with unique modes of action and impact on disease outcome have for the first time...

Dr. Ayalew Tefferi of Mayo discusses December Mayo Clinic Proceedings article on primary myelofibrosis

submitted by: mcgheekkm
Dr. Ayalew Tefferi, Professor of Hematology and Medicine at Mayo Clinic in Rochester, MN, discusses the findings of the largest ever study with the most mature data currently available of patients with primary myelofibrosis younger than 60 years. These 176 patients were followed up for a median of 8 years or until death. Improvement in survival was noted in those with high- and moderate-risk disease but not in those with low-risk disease. These findings suggest a salutary effect of recent...

Disease Associations With MGUS--Mayo Clinic study published in Mayo Clinic Proceedings

submitted by: mcgheekkm

Dr. S. Vincent Rajkumar, Mayo Clinic hematologist, discusses the first systematic study (published in August issue of Mayo Clinic Proceedings available at http://tinyurl.com/lr55lc) to determine association of Monoclonal Gammopathy of Undetermined Significance (MGUS) with all diseases in 17,398 patients.